Advancing our innovative pipeline
to address unmet needs

Overview

We are applying our TransCon technology to build a leading, fully integrated biopharmaceutical company with an independent pipeline of long-acting prodrug therapies that address unmet needs. In addition to our current pipeline of three rare disease endocrinology candidates, we have established oncology as our second therapeutic area of focus.